CSBIO(SZ:300255) Xin Lang Cai Jing·2025-10-20 02:50Core Viewpoint - Changshan Pharmaceutical's stock has shown significant growth this year, with a year-to-date increase of 148.82%, despite recent fluctuations in trading volume and net capital flow [1][2]. Group 1: Stock Performance - As of October 20, Changshan Pharmaceutical's stock price reached 49.74 CNY per share, with a market capitalization of 457.14 billion CNY [1]. - The stock has experienced a 2.05% increase during the trading session on October 20, with a trading volume of 3.56 billion CNY and a turnover rate of 0.80% [1]. - The stock has been on the "龙虎榜" (a list of stocks with significant trading activity) five times this year, with the most recent appearance on June 19, where it recorded a net buy of -178 million CNY [1]. Group 2: Financial Performance - For the first half of 2025, Changshan Pharmaceutical reported a revenue of 4.92 billion CNY, a year-on-year decrease of 13.42%, while the net profit attributable to shareholders was -29.09 million CNY, an increase of 37.98% year-on-year [2]. - The company's main business revenue composition includes 47.47% from water injection preparations, 39.24% from heparin raw materials, and 13.29% from other products [1]. Group 3: Shareholder Information - As of October 10, the number of shareholders for Changshan Pharmaceutical was 45,700, a decrease of 2.04% from the previous period, with an average of 20,094 circulating shares per shareholder, an increase of 2.08% [2]. - The company has distributed a total of 1.81 billion CNY in dividends since its A-share listing, with 4.60 million CNY distributed over the past three years [3]. - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth-largest circulating shareholder, holding 10.55 million shares, an increase of 8.04 million shares from the previous period [3].